ARI SHAPIRO, HOST:

First to the Supreme Court docket, which entered the abortion debate once more right now. It agreed to assessment a decrease court docket resolution that may make the generally used abortion capsule mifepristone much less accessible. A Supreme Court docket resolution on this case, which might come subsequent 12 months, couldn’t solely have an effect on the way in which the FDA does its job, but additionally have a serious impression on the presidential election. NPR politics correspondent Danielle Kurtzleben and prescription drugs correspondent Sydney Lupkin are right here to clarify what’s at stake. Good to have you ever each with us.

SYDNEY LUPKIN, BYLINE: Hey, Ari.

DANIELLE KURTZLEBEN, BYLINE: Hello.

SHAPIRO: Danielle, let’s begin with you. Inform us in regards to the case the Supreme Court docket’s going to listen to.

KURTZLEBEN: Positive. So this case is in regards to the availability of mifepristone, which is one in every of two medication utilized in treatment abortions. On this case, an antiabortion rights group referred to as the Alliance for Hippocratic Medication introduced a go well with in opposition to the FDA, partially arguing in opposition to laws on mifepristone which were loosened over time. They do not assume it ought to have been loosened. Beginning in 2016, there have been numerous adjustments. For instance, the FDA made prescriptions obtainable through telemedicine and made it attainable to ship the capsules to sufferers by way of the mail. Now, on this case, the Fifth Circuit Court docket of Appeals stated these laws should not have been loosened. They agreed with the plaintiffs. They stated that the drug should not be so extensively obtainable.

Now, had the Supreme Court docket not determined right now to take this up, that may imply these tighter curbs on the drug would stand. However since they are going to take this up, mifepristone will stay obtainable for now, in its present type. However a Supreme Court docket ruling, when it comes, might imply tighter restrictions on the drug, or it may not. It completely relies upon.

SHAPIRO: OK, so the drug remains to be obtainable…

KURTZLEBEN: Sure.

SHAPIRO: …For now at the very least. However, Sydney, what are the stakes right here? What might change?

LUPKIN: Yeah, I imply, mifepristone is, like Danielle stated, utilized in treatment abortions. And people now account for greater than half of abortions in america. The drug was authorized in 2000, and it was an enormous deal within the U.S. as a result of it was the primary time ladies right here might finish their pregnancies without having to endure a surgical process. However globally, it truly wasn’t a groundbreaking approval. Mifepristone had been authorized as much as a dozen years in different international locations by that time. So there was loads of proof it was secure and efficient. And naturally, there’s much more now that it has been authorized within the U.S. for 23 years.

General, mifepristone will increase entry to abortion care and might presently be used as much as 10 weeks gestation. Rolling again that approval to those pre-2016 restrictions would restrict that entry. The drug works by blocking a hormone wanted for being pregnant to proceed – that is referred to as progesterone. And it is often taken with a second drug, misoprostol, 24 hours later, which causes the uterus to contract after which empty.

SHAPIRO: However misoprostol’s approval will not be on the chopping block, proper?

LUPKIN: Proper. That is proper. That is nearly mifepristone. There are misoprostol-only abortions, and people might proceed even when the court docket tightens restrictions on mifepristone. However misoprostol-only abortions are thought of much less efficient and extra painful than abortions utilizing each medication collectively. And if this case is profitable, abortion opponents might give you a solution to take motion in opposition to misoprostol subsequent.

SHAPIRO: This opinion might come two years after the Supreme Court docket overturned Roe v. Wade. Danielle, how a lot might this case additional change the abortion panorama within the U.S.?

KURTZLEBEN: Very, very a lot, in a very large method. Like I stated earlier, this ruling, relying on how the justices rule – it might imply that sufferers can get the drug much less simply. For instance, if justices determined to roll again laws to that pre-2016 standing, it might imply, for instance, that capsules aren’t despatched by way of the mail anyplace, even in states the place abortion is authorized proper now. And this may even be an enormous deal, notably for sufferers in states the place abortion is tightly restricted, as a result of proper now, these sufferers can nonetheless get the capsules by way of the mail.

So a technique to consider this very merely is that this – is that the Dobbs ruling overturning Roe despatched abortion again to the states. States might decide, up to a degree, what their abortion legal guidelines seem like. This case would, in some methods, have an effect on abortion availability nationwide. That may be a actually large deal. However there’s one different factor to notice right here – is that, sure, the justices might tighten the restrictions or not. However they may additionally merely say, in accordance with authorized students, that plaintiffs did not have authorized standing right here – that this was not their case to carry – now, during which case the justices would not rule on the legality of the arguments that they are making. They’d simply say laws keep the place they’re proper now. We’re probably not taking this up.

SHAPIRO: Sydney, you cowl the prescription drugs business. What might this imply for drug corporations?

LUPKIN: So this may set a precedent for court docket interference in FDA skilled decision-making. For many years, the FDA has been the worldwide chief in approving numerous medication based mostly on rigorous security and efficacy requirements. And now a court docket – not the FDA’s medical doctors and scientists – a court docket might undo that. Here is Professor Robin Feldman on the College of California Regulation in San Francisco.

ROBIN FELDMAN: If the choice is broad sufficient to depart room to problem all of these, the company could possibly be below appreciable assault within the years to come back.

LUPKIN: The FDA would not wish to be sued. For one factor, it is costly, so it might make the company extra cautious in terms of medication which can be politically charged. Assume medication for HIV, medication for gender-affirming care. And firms may not wish to put money into creating some medication if, even after assembly FDA requirements and profitable that approval, the approval can simply be undone or restricted by the courts. So it makes that enterprise funding much more dangerous. And the business has argued that it’ll have a chilling impact on innovation.

SHAPIRO: After which there’s the politics.

KURTZLEBEN: Proper.

SHAPIRO: If the Supreme Court docket decides one other landmark abortion case throughout a presidential election 12 months, Danielle, what might that imply?

KURTZLEBEN: It might imply lots. It relies upon, after all, on how they rule. However one factor we all know from the 2022 midterms, proper after the Dobbs resolution, and likewise that we all know from this 12 months’s off-year elections – for instance, in Virginia – is that abortion, proper now, at the very least, actually will get Democrats and Democratic-leaning voters actually fired up. They’re very upset in regards to the overturning of Roe, after all. So have been the Supreme Court docket to tighten these guidelines on mifepristone, it could be an enormous blow for pro-abortion rights teams, and Democrats would additionally undoubtedly run on abortion rights. We already know this.

For instance, the Biden marketing campaign put out a press release right now. It says MAGA Republicans, led by Donald Trump, are marching this nation towards a full-on nationwide abortion ban. And if the Supreme Court docket strips away entry to secure and efficient treatment abortion subsequent 12 months, it is going to be the most recent step in direction of reaching that objective. That could be very strident language from the Biden marketing campaign. You’ll be able to guess this may change into a completely large subject within the 2024 presidential election if the Supreme Court docket determined to limit the capsules, which, once more, we’ll need to see subsequent 12 months.

SHAPIRO: However we all know, as of right now, they’re at the very least going to listen to the case.

KURTZLEBEN: Appropriate.

SHAPIRO: Reporting there from NPR is Danielle Kurtzleben and Sydney Lupkin. Thanks each.

LUPKIN: Thanks.

KURTZLEBEN: You guess.

Copyright © 2023 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional data.

NPR transcripts are created on a rush deadline by an NPR contractor. This textual content will not be in its closing type and could also be up to date or revised sooner or later. Accuracy and availability could differ. The authoritative document of NPR’s programming is the audio document.